Supplementary Material for: Serum Autotaxin Level Positively Associates with Metabolic Associated Fatty Liver Disease and Hyperuricemia in Postmenopausal Women

Introduction: Autotaxin is an adipokine known to affect energy metabolism and lipid homeostasis. We aimed to evaluate serum autotaxin levels in metabolic associated fatty liver disease (MAFLD) and other metabolic disorders in postmenopausal women. Methods: Postmenopausal women who received an annual health examination were included. The metabolic and demographic characteristics of the subjects were collected, including age, gender, weight, height, blood pressure, and biochemical parameters. Serum autotaxin level was determined by ELISA. Results: This cross-sectional includes 20 postmenopausal women and 20 age-paired healthy controls. MAFLD patients showed significant metabolic disturbance presented with increased BMI, blood pressure (P＜0.001) and decreased HDL-C (P＜0.05), as well as liver injury companied by elevated ALT (P＜0.05). Serum autotaxin levels were statistically higher in MAFLD (253.1±52.1 vs. 202.2±53.2 ng/mL; P < 0.01) and positively correlated with ALT (P＜0.001), GGT and BMI (P＜0.01), SBP and TG (P＜0.05). Higher autotaxin group demonstrated worsen metabolic states with greater proportion of MAFLD, higher BMI (P＜0.01) and ALT (P＜0.05). Logistic regression analysis revealed that serum autotaxin levels would positively independently predicted MAFLD (OR 1.049, 95% CI 1.001-1.098, P＜0.05) with AUC of 0.763. Serum level of autotaxin is significantly elevated in hyperuricemia group (257.3±60.9 vs. 214.5±49.4 ng/mL; P < 0.05), and positively correlated with uric acid level (P＜0.01). Serum autotaxin would also act as diagnosing parameter of hyperuricemia with AUC of 0.706. Conclusions: Among postmenopausal women, serum autotaxin level is significantly elevated in MAFLD and related to multiple metabolic characteristics, especially hyperuricemia, which would thus serve as a potential non-invasive biomarker as well as a therapeutic target.引言：自分泌运动因子（autotaxin）是一种已知可影响能量代谢与脂质稳态的脂肪因子。本研究旨在评估绝经后女性代谢相关脂肪性肝病（MAFLD）及其他代谢紊乱患者的血清自分泌运动因子水平。方法：纳入接受年度健康体检的绝经后女性。收集研究对象的代谢与人口统计学特征，包括年龄、性别、体重、身高、血压及生化指标。采用酶联免疫吸附测定（ELISA）法检测血清自分泌运动因子水平。结果：本横断面研究共纳入20例绝经后女性及20例年龄匹配的健康对照。代谢相关脂肪性肝病患者存在显著代谢紊乱，表现为体重指数（BMI）升高、血压升高（P＜0.001）、高密度脂蛋白胆固醇（HDL-C）降低（P＜0.05），同时伴有肝损伤，表现为丙氨酸氨基转移酶（ALT）升高（P＜0.05）。血清自分泌运动因子水平在代谢相关脂肪性肝病患者中显著升高（253.1±52.1 vs. 202.2±53.2 ng/mL；P < 0.01），且与ALT（P＜0.001）、γ-谷氨酰转移酶（GGT）及BMI（P＜0.01）、收缩压（SBP）及甘油三酯（TG）（P＜0.05）呈正相关。高自分泌运动因子组患者代谢状态更差，代谢相关脂肪性肝病患病率更高，BMI（P＜0.01）及ALT水平（P＜0.05）更高。Logistic回归分析显示，血清自分泌运动因子水平可独立正向预测代谢相关脂肪性肝病（优势比[OR] 1.049，95%置信区间[CI] 1.001~1.098，P＜0.05），受试者工作特征曲线下面积（AUC）为0.763。高尿酸血症组患者血清自分泌运动因子水平显著升高（257.3±60.9 vs. 214.5±49.4 ng/mL；P < 0.05），且与尿酸水平呈正相关（P＜0.01）。血清自分泌运动因子亦可作为高尿酸血症的诊断标志物，AUC为0.706。结论：在绝经后女性中，血清自分泌运动因子水平在代谢相关脂肪性肝病患者中显著升高，且与多种代谢特征相关，尤其是高尿酸血症，因此其有望成为潜在的非侵入性生物标志物及治疗靶点。